Oxytocin alterations and neurocognitive domains in patients with hypopituitarism
Oxytocin is a hypothalamus derived, posterior pituitary stored nonapeptide which has gained recent interest as an important neuropsychiatric and metabolic hormone beyond its classic role in lactation and parturition. Hypopituitarism is a heterogenous disorder of derangement in one or more anterior or posterior pituitary hormones. Diagnosis of deficiency and hormone replacement exists to address all relevant axes except for oxytocin. Our study aims to define derangements in oxytocin in a unique population of patients with hypopituitarism and correlate levels with measures of emotional health and quality of life.
A cross-sectional, single day study was completed to measure plasma oxytocin levels in a diverse population of patients with hypopituitarism compared to controls. Subjects also completed depression, quality of life and stress-related questionnaires, and emotion recognition tasks.
Thirty-eight subjects completed the study, 18 with hypopituitarism (9 with diabetes insipidus) and 20 controls. After controlling for differences in age, weight and gender, plasma oxytocin levels were highest in subjects with diabetes insipidus compared to control [mean, IQR: 44.3 pg/ml (29.8–78.2) vs. 20.6 (17–31.3), p = 0.032]. Amongst hypopituitary subjects, those with duration of disease greater than 1 year had higher oxytocin levels. No significant differences were observed for psychosocial measures including emotion recognition tasks.
Plasma oxytocin levels were found higher in patients with hypopituitarism compared to controls and highest in those with diabetes insipidus. Longer duration of hypopituitarism was also associated with higher plasma levels of oxytocin. Further study is needed to better define oxytocin deficiency and investigate response to treatment.
KeywordsOxytocin Hypopituitarism Diabetes Insipidus Neurocognition
We would also like to acknowledge Dr. Toni Zeigler and her laboratory for assisting in oxytocin measures. Grant support: BTL was supported by the National Institutes of Health under award number, R01DK104927-01A1 and Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, VA merit (Grant No. 1I01BX003382).
Compliance with ethical standards
The authors have nothing to declare.
- 1.Robinson AG, Verbalis JG (2011) Posterior pituitary gland. Williams textbook of endocrinology, 12th edn. Elsevier Inc., PhiladelphiaGoogle Scholar
- 4.Zhang H, Wu C, Chen Q, Chen X, Xu Z, Wu J et al (2013) Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. PLoS ONE 8:1–11Google Scholar
- 16.Blum WF, Shavrikova EP, Edwards DJ, Rosilio M, Hartman ML, Marín F et al (2003) Decreased quality of life in adult patients with growth hormone deficiency compared with general populations using the new, validated, self-weighted questionnaire, Questions on Life Satisfaction Hypopituitarism Module. J Clin Endocrinol Metab 88:4158–4167CrossRefPubMedGoogle Scholar
- 22.Kanade T, Cohn J, Tian Y (2000) Comprehensive database for facial expression analysis. In: Proceedings of the international conference on automatic face and gesture recognition, pp 46–53Google Scholar
- 23.Porges SW, Cohn JF, Bal E, Lamb D, Lewis GF (2016) The dynamic affect recognition evaluation software v2. Brain-Body Center for Psychophysiology and BioengineeringGoogle Scholar
- 24.Eaton W, Muntaner C, Smith C, Tien A, Ybarra M (2004) Center for Epidemiologic Studies Depression Scale: review and revision (CESD and CESD-R). In: Maruish M (ed) The use of psychological testing for treatment planning and outcomes assessment, 3rd edn. Lawrence Erlbaum, Mahwah, pp 363–377Google Scholar
- 41.Oxytocin ELISA, Kit, Enzo Life Sciences Inc. [Internet]. 2018 [Cited 8 Feb 2018]. http://www.enzolifesciences.com/ADI-901-153A/oxytocin-elisa-kit/